BIOMAT Database Logo BIOMAT Database Logo

New ribonucleotide reductase inhibitors with antineoplastic activity. 1979

H L Elford, and G L Wampler, and B van't Riet

UI MeSH Term Description Entries
D007939 Leukemia L1210 An experimental LYMPHOCYTIC LEUKEMIA of mice. Leukemia L 1210,L 1210, Leukemia,L1210, Leukemia
D008815 Mice, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation. Inbred Mouse Strains,Inbred Strain of Mice,Inbred Strain of Mouse,Inbred Strains of Mice,Mouse, Inbred Strain,Inbred Mouse Strain,Mouse Inbred Strain,Mouse Inbred Strains,Mouse Strain, Inbred,Mouse Strains, Inbred,Strain, Inbred Mouse,Strains, Inbred Mouse
D005260 Female Females
D006877 Hydroxamic Acids A class of weak acids with the general formula R-CONHOH. Hydroxamic Acid,Acid, Hydroxamic,Acids, Hydroxamic
D006918 Hydroxyurea An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. Hydroxycarbamid,Hydrea,Oncocarbide
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D012264 Ribonucleotide Reductases Ribonucleotide Reductase,Reductase, Ribonucleotide,Reductases, Ribonucleotide
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

H L Elford, and G L Wampler, and B van't Riet
DNA-protective activity of new ribonucleotide reductase inhibitors.
January 1997, Anticancer research,
H L Elford, and G L Wampler, and B van't Riet
Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy.
March 1996, Critical reviews in oncology/hematology,
H L Elford, and G L Wampler, and B van't Riet
Structure-activity relationships of benzohydroxamic acid inhibitors of ribonucleotide reductase.
July 1980, Journal of pharmaceutical sciences,
H L Elford, and G L Wampler, and B van't Riet
Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity.
January 1999, Advances in enzyme regulation,
H L Elford, and G L Wampler, and B van't Riet
Thionucleotides as inhibitors of ribonucleotide reductase.
January 2003, Nucleosides, nucleotides & nucleic acids,
H L Elford, and G L Wampler, and B van't Riet
Radical scavengers as ribonucleotide reductase inhibitors.
January 2012, Current topics in medicinal chemistry,
H L Elford, and G L Wampler, and B van't Riet
Peptide inhibitors of mammalian ribonucleotide reductase.
January 2005, Advances in enzyme regulation,
H L Elford, and G L Wampler, and B van't Riet
MEK2 regulates ribonucleotide reductase activity through functional interaction with ribonucleotide reductase small subunit p53R2.
September 2012, Cell cycle (Georgetown, Tex.),
H L Elford, and G L Wampler, and B van't Riet
Development of ribonucleotide reductase inhibitors: a review on structure activity relationships.
November 2013, Mini reviews in medicinal chemistry,
H L Elford, and G L Wampler, and B van't Riet
Synthesis and biological activity of cyclic peptide inhibitors of ribonucleotide reductase.
October 1999, Organic letters,
Copied contents to your clipboard!